From treating rashes to uncovering a case of osteoarthritis, dermatologists and rheumatologists can work together in a variety of ways to improve patient care, says Joseph F. Merola, MD, MMSc…
Search results for: hospital
ACR Releases New Position Statements on Site of Service & Compounding
Patient Safety & Site of Service for Biologics Although emphasizing its strong support for the use of biologic agents as necessary treatments for rheumatic diseases, the ACR Board of Directors continues to be concerned about the safe delivery of these agents, given the potential for associated adverse events and infusion reactions. In a position statement…
Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
Certolizumab pegol has proved safe and effective for treating patients with plaque psoriasis in a Phase 3 clinical trial…
FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis
The FDA is considering a supplemental biologics license application for tocilizumab to treat giant cell arteritis…
Peripheral Helper Cells May Provide Clue to RA Pathology
Research has identified a subset of T cells, peripheral helper (TPH) cells, which may promote pathological B cell responses and antibody production in patients with seropositive RA. TPH cells also express chemokine receptors, enabling them to infiltrate inflamed parts of the body and stimulate B cells to produce antibodies…
Online Treatment Reduces Chronic Knee Pain from Arthritis
(Reuters Health)—A web-based program of exercise and coping skills training improves both function and pain in arthritic knees, a new study suggests. This kind of online therapy can greatly improve access to effective, nonsurgical and non-drug relief for people with osteoarthritis of the knee, researchers say. “Osteoarthritis is a leading cause of chronic knee pain…
Volatility of the Gut Microbiome Tied to IBD
NEW YORK (Reuters Health)—Fluctuations in the gut microbiome over time could underlie inflammatory bowel disease (IBD), including Crohn’s and ulcerative colitis, researchers suggest. “Both the state and the dynamics of the human gut microbiome in healthy individuals are highly personalized. Although cross-sectional studies have revealed dysbiosis of the gut microbiome in IBD, little is known…
Physician’s Choice: Factors That Influence First- & Second-Line Biologic Therapy in RA Patients
In patients with RA, age and higher rates of comorbidity are influential in selecting and changing treatments…
Celecoxib Is a Safe Treatment for Arthritis
A study compared celecoxib with ibuprofen and naproxen to determine its cardiovascular safety, as well as gastrointestinal and renal outcomes, in patients with rheumatoid arthritis and osteoarthritis. The results showed that celecoxib met all prespecified noninferiority requirements and is as safe as other non-selective NSAIDs…
Switch to Biosimilar Infliximab for IBD Slashes Drug Costs
NEW YORK—Inflammatory bowel disease (IBD) patients can be safely switched from originator infliximab to biosimilar infliximab using a managed-switching program, U.K. research shows. “Thus far, there does not appear to be any significant difference between the two infliximab products in terms of drug persistence, side effects, adverse reactions, disease activity, or blood tests, but ongoing…
- « Previous Page
- 1
- …
- 186
- 187
- 188
- 189
- 190
- …
- 319
- Next Page »